PHIA Koninklijke Philips N.V.

Philips and Flevo Hospital sign long-term strategic partnership agreement enabling continuous innovation and optimization of patient care

Philips and Flevo Hospital sign long-term strategic partnership agreement enabling continuous innovation and optimization of patient care



July 14, 2020

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Flevo Hospital today announced they have signed a 10-year strategic partnership agreement to continuously innovate and optimize patient care in the Almere region of the Netherlands.

The collaboration has four strategic priorities: 1) Achieving the strategic objective of 'the right care in the right place' by means of innovations and the optimal use of (medical) technology; 2) Modernizing care and strengthening communication between Flevo Hospital and its patients and partners; 3) Increasing the enthusiasm and involvement of hospital employees by unburdening care professionals and modernizing work processes; and 4) Saving costs and improving the efficiency of technology.

“We are confronted with many new challenges, but want to keep providing a high standard of affordable care not only within the hospital but also increasingly outside the hospital,” said Anita Arts, CEO of Flevo Hospital, Almere, the Netherlands. “We want to involve our patients even more closely in their care. This is possible with the help of technological solutions. Philips is a partner for the future with whom we want to innovate and develop new solutions for our strategic challenges.”

“Thanks to our broad portfolio, we can help Flevo Hospital achieve its ambitions and overcome the challenges it faces,” said Henk Valk, CEO at Philips Benelux. “In this collaboration, we will work as partners to realize a future-proof hospital. Innovation is the most important part, but good education, together with the maintenance and service of our technology, are also enormously important for the Flevo Hospital to be able to deliver high-quality patient care. In every way, we can strengthen each other and help to improve care, making cooperations like this crucial now and into the future.”

During the term of the contract, Philips will act as the preferred supplier of imaging systems, such as MR, CT and ultrasound, and patient monitoring systems. The purchase of equipment is organized through a multi-year medical technology plan to reduce costs for the hospital and make it more transparent. Flevo Hospital will gain early insight into new Philips solutions to ensure that the right equipment is purchased at the right time. The ambition of Flevo Hospital is to be able to quickly use new innovative Philips solutions to optimize workflows, patient pathways and patient experiences while driving efficiencies and cost optimization.

Under the agreement, Philips and Flevo Hospital will also work on innovation programs aimed at introducing innovative technologies and ensuring their optimal use, such as expanding patient monitoring in the hospital, as well as facilitating care outside the hospital. Another goal focuses on further enhancing the staff experience to foster passionate and committed employees. Each year, an education plan will be agreed on for the development and education of healthcare providers and medical technicians in the hospital, so that Philips' technology can be used optimally and efficiently for patient care.

For further information, please contact:

Joost Maltha

Philips Global Press Office

Tel.: 16

E-mail:

Pieter de Meer

Philips Benelux

Tel.: 65

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachment

EN
14/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips publishes its Annual Report 2025

Philips publishes its Annual Report 2025 February 19, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course. Philips filed the Annual Report 2025 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to f...

 PRESS RELEASE

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI ...

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort February 12, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. Designed specifically for pediatric patients, the Snuggle coil has been optimized and validated for use with Philips 3.0T MRI systems, bringing enhanced comfort for children and efficient, high-quality i...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN Amro: Miss but strong capital, good set of results / Ahold Delhaize: Strong 4Q25 but no major surprise on FY26 adj. EPS guidance / Alfen: No recovery yet and another transitional year / BAM Group: Preview: 2026 outlook the key item / Econocom: Better REBITA, net debt, but EBIT below, much lower net profit, dividend halved, 2026-28 guidance postponed to “medium term” / Exor: Ferrari 4Q25 and 2026 guidance beat / Gecina: Results and guidance in line, DPS set to grow over 2026-30 / Heineken: No...

Oscar Rodriguez
  • Oscar Rodriguez

PHILIPS: RDOS. 4T’25 Y CAMBIO DE P.O. AL ALZA (ANÁLISIS BANCO SABADELL...

Rdos. 4T’25 vs 4T’24: Ventas: 5.097 M euros (+1,1% vs -0,9% BS(e) y -1,0% consenso); EBITA Aj.: 770 M euros (+13,4% vs +0,6% BS(e) y -1,0% consenso); BDI: 397 M euros (-333 M euros en 2024 vs 275 M euros BS(e) y 276 M euros consenso); Rdos. 2025 vs 2024: Ventas: 17.834 M euros (-1,0% vs -1,6% BS(e) y -1,6% consenso); EBITA Aj.: 2.195 M euros (+5,7% vs +1,5% BS(e) y +1,0% consenso); BDI: 897 M euros (-698 M euros en 2024 vs 775 M euros BS(e) y 776 M euros consenso).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch